<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Keen Vision Acquisition Corporation Units — News on 6ix</title>
<link>https://6ix.com/company/keen-vision-acquisition-corporation-units</link>
<description>Latest news and press releases for Keen Vision Acquisition Corporation Units on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 15 Jul 2025 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/keen-vision-acquisition-corporation-units" rel="self" type="application/rss+xml" />
<item>
<title>Medera and University of Kansas Medical Center Announce First Patient Treated in Pioneering Gene Therapy Trial for Duchenne Muscular Dystrophy Associated Cardiomyopathy</title>
<link>https://6ix.com/company/keen-vision-acquisition-corporation-units/news/medera-and-university-of-kansas-medical-center-announce-first-patient-treated-in-pioneering-gene-therapy-trial-for-duchenne-muscular-dystrophy-associated-cardiomyopathy-1</link>
<guid isPermaLink="true">https://6ix.com/company/keen-vision-acquisition-corporation-units/news/medera-and-university-of-kansas-medical-center-announce-first-patient-treated-in-pioneering-gene-therapy-trial-for-duchenne-muscular-dystrophy-associated-cardiomyopathy-1</guid>
<pubDate>Tue, 15 Jul 2025 12:00:00 GMT</pubDate>
<description>Landmark MUSIC-DMD Phase 1b trial represents first-in-human gene therapy approach for DMD-associated heart failureBOSTON and KANSAS CITY, Kan., July 15, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, and its clinical development division Sardocor, together with the University of Kansas Medical Center, today announced the successful treatment of the first patient i</description>
</item>
<item>
<title>Medera’s Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome</title>
<link>https://6ix.com/company/keen-vision-acquisition-corporation-units/news/mederas-novoheart-enters-new-collaboration-to-develop-human-mini-heart-models-aimed-at-transforming-treatment-for-hypoplastic-left-heart-syndrome-1</link>
<guid isPermaLink="true">https://6ix.com/company/keen-vision-acquisition-corporation-units/news/mederas-novoheart-enters-new-collaboration-to-develop-human-mini-heart-models-aimed-at-transforming-treatment-for-hypoplastic-left-heart-syndrome-1</guid>
<pubDate>Tue, 24 Jun 2025 12:00:00 GMT</pubDate>
<description>First-ever mini-Heart models will be created from hypoplastic left heart syndrome (HLHS) patient stem cells, enabling personalized insights into their causes and treatmentsPartnership aims to improve survival and quality of life for pediatric HLHS patients by developing new tools that can identify which children will potentially benefit most from surgery, transplantation, or novel therapiesLeveraging Novoheart’s proprietary mini-Heart Platform, this partnership aligns with emerging FDA guideline</description>
</item>
<item>
<title>Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress</title>
<link>https://6ix.com/company/keen-vision-acquisition-corporation-units/news/medera-showcased-positive-interim-data-from-first-in-human-gene-therapy-trial-for-hfpef-in-late-breaking-presentation-at-heart-failure-2025-congress-1</link>
<guid isPermaLink="true">https://6ix.com/company/keen-vision-acquisition-corporation-units/news/medera-showcased-positive-interim-data-from-first-in-human-gene-therapy-trial-for-hfpef-in-late-breaking-presentation-at-heart-failure-2025-congress-1</guid>
<pubDate>Mon, 19 May 2025 12:00:00 GMT</pubDate>
<description>Results from MUSIC-HFpEF Phase 1/2a clinical trial show favorable safety profile and early clinical benefits with SRD-002 gene therapy BOSTON, May 19, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that positive interim data from its ongoing MUSIC-HFpEF Phase 1/2a clinical trial was presented at the Heart Failure 2025 Congress taking pla</description>
</item>
<item>
<title>Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress</title>
<link>https://6ix.com/company/keen-vision-acquisition-corporation-units/news/medera-to-present-late-breaking-phase-12a-clinical-trial-results-at-heart-failure-2025-congress-1</link>
<guid isPermaLink="true">https://6ix.com/company/keen-vision-acquisition-corporation-units/news/medera-to-present-late-breaking-phase-12a-clinical-trial-results-at-heart-failure-2025-congress-1</guid>
<pubDate>Mon, 12 May 2025 12:00:00 GMT</pubDate>
<description>BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that data from its First-In-Human Phase 1/2a MUSIC-HFpEF clinical trial investigating its adeno-associated virus-based gene therapy candidate SRD-002 in heart failure with preserved ejection fraction (HFpEF) will be presented at the upcoming Heart Failure 2025 Congress taking</description>
</item>
<item>
<title>Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology</title>
<link>https://6ix.com/company/keen-vision-acquisition-corporation-units/news/medera-announces-publication-of-study-utilizing-machine-learning-to-enhance-next-generation-drug-screening-with-human-mini-heart-technology</link>
<guid isPermaLink="true">https://6ix.com/company/keen-vision-acquisition-corporation-units/news/medera-announces-publication-of-study-utilizing-machine-learning-to-enhance-next-generation-drug-screening-with-human-mini-heart-technology</guid>
<pubDate>Thu, 31 Oct 2024 04:00:00 GMT</pubDate>
<description>Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant</description>
</item>
<item>
<title>Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction</title>
<link>https://6ix.com/company/keen-vision-acquisition-corporation-units/news/medera-announces-completion-of-cohort-a-and-initiation-of-dosing-in-cohort-b-of-music-hfpef-a-phase-12a-clinical-trial-evaluating-first-in-human-gene-therapy-srd-002-for-heart-failure-with-preserved-ejection-fraction</link>
<guid isPermaLink="true">https://6ix.com/company/keen-vision-acquisition-corporation-units/news/medera-announces-completion-of-cohort-a-and-initiation-of-dosing-in-cohort-b-of-music-hfpef-a-phase-12a-clinical-trial-evaluating-first-in-human-gene-therapy-srd-002-for-heart-failure-with-preserved-ejection-fraction</guid>
<pubDate>Thu, 24 Oct 2024 04:00:00 GMT</pubDate>
<description>Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per yearHeart failure with preserved ejection fraction</description>
</item>
<item>
<title>Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation</title>
<link>https://6ix.com/company/keen-vision-acquisition-corporation-units/news/medera-inc-to-be-listed-on-nasdaq-through-a-merger-agreement-with-keen-vision-acquisition-corporation</link>
<guid isPermaLink="true">https://6ix.com/company/keen-vision-acquisition-corporation-units/news/medera-inc-to-be-listed-on-nasdaq-through-a-merger-agreement-with-keen-vision-acquisition-corporation</guid>
<pubDate>Thu, 05 Sep 2024 04:00:00 GMT</pubDate>
<description>Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and</description>
</item>
<item>
<title>Keen Vision Acquisition Corporation Announces the Separate Trading of its Ordinary Shares and Warrants, Commencing September 15, 2023</title>
<link>https://6ix.com/company/keen-vision-acquisition-corporation-units/news/keen-vision-acquisition-corporation-announces-the-separate-trading-of-its-ordinary-shares-and-warrants-commencing-september-15-2023</link>
<guid isPermaLink="true">https://6ix.com/company/keen-vision-acquisition-corporation-units/news/keen-vision-acquisition-corporation-announces-the-separate-trading-of-its-ordinary-shares-and-warrants-commencing-september-15-2023</guid>
<pubDate>Thu, 14 Sep 2023 04:00:00 GMT</pubDate>
<description>SUMMIT, N.J., Sept. 14, 2023 /PRNewswire/ -- Keen Vision Acquisition Corporation ("KVAC") announced today that, commencing September 15, 2023, holders of the</description>
</item>
<item>
<title>Keen Vision Acquisition Corporation Announces Closing of $149,500,000 Initial Public Offering and Full Exercise of Over-Allotment Option</title>
<link>https://6ix.com/company/keen-vision-acquisition-corporation-units/news/keen-vision-acquisition-corporation-announces-closing-of-dollar149500000-initial-public-offering-and-full-exercise-of-over-allotment-option</link>
<guid isPermaLink="true">https://6ix.com/company/keen-vision-acquisition-corporation-units/news/keen-vision-acquisition-corporation-announces-closing-of-dollar149500000-initial-public-offering-and-full-exercise-of-over-allotment-option</guid>
<pubDate>Thu, 27 Jul 2023 04:00:00 GMT</pubDate>
<description>SUMMIT, N.J., July 27, 2023 /PRNewswire/ -- Keen Vision Acquisition Corporation (the "Company") announced today the closing of its initial public offering of</description>
</item>
<item>
<title>Keen Vision Acquisition Corporation Announces Pricing of $130,000,000 Initial Public Offering</title>
<link>https://6ix.com/company/keen-vision-acquisition-corporation-units/news/keen-vision-acquisition-corporation-announces-pricing-of-dollar130000000-initial-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/keen-vision-acquisition-corporation-units/news/keen-vision-acquisition-corporation-announces-pricing-of-dollar130000000-initial-public-offering</guid>
<pubDate>Mon, 24 Jul 2023 04:00:00 GMT</pubDate>
<description>SUMMIT, N.J., July 24, 2023 /PRNewswire/ -- Keen Vision Acquisition Corporation (the "Company") announced today that it priced its initial public offering of</description>
</item>
</channel>
</rss>